Sun Pharmaceutical Industries Ltd. Q3 FY2025 results: revenue ₹13,675 crore, up 10.5% on the year
Sun Pharmaceutical Industries Ltd. (SUNPHARMA) reported consolidated revenue from operations of ₹13,675 crore for Q3 FY2025, the quarter ended 31 December 2024, up 10.5% on the same quarter a year earlier. Profit after tax was ₹2,913 crore, up 13.8% on the year, and earnings per share ₹12.10. The figures are the company's own, from the unaudited results it filed with NSE on 31 January 2025.
The quarter, against the one before and a year earlier
| Line | Q3 FY2025 | Q2 FY2025 | Q3 FY2024 | Change on the year |
|---|---|---|---|---|
| Revenue from operations | 13,675 | 13,291 | 12,381 | +10.5% |
| Other income | 466 | 354 | 250 | +86.1% |
| Total income | 14,141 | 13,645 | 12,631 | +12.0% |
| Cost of materials consumed | 1,408 | 1,639 | 1,710 | -17.6% |
| Purchases of stock-in-trade | 1,239 | 875 | 796 | +55.5% |
| Changes in inventories | 94 | 180 | 231 | -59.5% |
| Employee benefit expense | 2,552 | 2,478 | 2,363 | +8.0% |
| Finance costs | 52 | 69 | 35 | +48.3% |
| Depreciation, depletion and amortisation | 631 | 626 | 622 | +1.4% |
| Other expenses | 4,374 | 4,181 | 3,804 | +15.0% |
| Total expenses | 10,349 | 10,048 | 9,561 | +8.2% |
| Profit before exceptional items and tax | 3,793 | 3,598 | 3,070 | +23.5% |
| Exceptional items | -316 | 0 | -70 | n/a |
| Profit before tax | 3,476 | 3,598 | 3,000 | +15.9% |
| Current tax | 559 | 567 | 432 | +29.3% |
| Deferred tax | 0 | 0 | 0 | n/a |
| Total tax | 559 | 567 | 432 | +29.3% |
| Profit after tax | 2,913 | 3,037 | 2,561 | +13.8% |
| Attributable to owners of the parent | 2,903 | 3,040 | 2,524 | +15.0% |
| Other comprehensive income | 118 | 418 | 425 | -72.2% |
| Total comprehensive income | 3,031 | 3,455 | 2,985 | +1.5% |
| EPS, basic | ₹12.10 | ₹12.70 | ₹10.50 | +15.2% |
| EPS, diluted | ₹12.10 | ₹12.70 | ₹10.50 | +15.2% |
₹ crore except per share.
Quarterly results, the last 12 quarters
| Q2 FY2024 | Q3 FY2024 | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 | Q4 FY2026 | Q1 FY2027 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 12,192 | 12,381 | 11,983 | 12,653 | 13,291 | 13,675 | 12,959 | 13,851 | 14,478 | 15,521 | 14,612 | 15,300 |
| Expenses | 9,695 | 9,561 | 9,672 | 9,762 | 10,048 | 10,349 | 9,956 | 10,325 | 10,781 | 11,383 | 11,519 | 11,721 |
| Operating profit | 3,179 | 3,477 | 3,035 | 3,608 | 3,939 | 4,009 | 3,716 | 4,302 | 4,527 | 4,948 | 3,954 | 4,418 |
| OPM % | 26% | 28% | 25% | 29% | 30% | 29% | 29% | 31% | 31% | 32% | 27% | 29% |
| Other income | 294 | 250 | 606 | 533 | 354 | 466 | 613 | 464 | 470 | 579 | 458 | 724 |
| Interest | 49 | 35 | 74 | 62 | 69 | 52 | 49 | 75 | 100 | 78 | 86 | 100 |
| Depreciation | 633 | 622 | 650 | 655 | 626 | 631 | 664 | 701 | 730 | 732 | 775 | 739 |
| Exceptional items | 0 | -70 | -102 | 0 | 0 | -316 | -362 | -818 | 0 | -489 | 0 | -204 |
| Profit before tax | 2,791 | 3,000 | 2,816 | 3,424 | 3,598 | 3,476 | 3,254 | 3,173 | 4,168 | 4,227 | 3,551 | 4,099 |
| Tax % | 14% | 14% | 5% | 16% | 16% | 16% | 34% | 27% | 25% | 20% | 23% | 29% |
| Net profit | 2,385 | 2,561 | 2,659 | 2,861 | 3,037 | 2,913 | 2,154 | 2,293 | 3,125 | 3,381 | 2,710 | 2,901 |
| EPS in ₹ | ₹9.90 | ₹10.50 | ₹11.10 | ₹11.80 | ₹12.70 | ₹12.10 | ₹9.00 | ₹9.50 | ₹13.00 | ₹14.00 | ₹11.30 | ₹12.10 |
| Filing | NSE | NSE | NSE | NSE | NSE | NSE | Filing | Filing | Filing | Filing | Filing | Filing |
₹ crore except per share, consolidated, as filed with the exchange. Operating profit is sales less the expenses other than interest and depreciation, OPM is that over sales, and tax % is tax over profit before tax: arithmetic on the filed lines; everything else is as filed. Quarters before December 2024 are from the exchange's earlier results feed, which carries the filed lines without the filing itself; the column links to the exchange's page for the company.
Source
Unaudited consolidated results for the quarter ended 31 December 2024, filed with NSE on 31 January 2025: the result statement. All of Sun Pharmaceutical Industries Ltd.'s results: NSE company page.
The same record on your computer
GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.